Dimension Therapeutics, Inc. (DMTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dimension Therapeutics, Inc. (DMTX) trades at $5.95 with AI Score 60/100 (Grade B+). Dimension Therapeutics, Inc. was a biopharmaceutical company focused on developing and delivering novel gene therapies for patients with rare diseases. Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for DMTX: DMTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DMTX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
DMTX: the 3 perspectives are evenly split. Dominant signal: Izzy Englander bearish.
How is this calculated? →Dimension Therapeutics, Inc. (DMTX) Healthcare & Pipeline Overview
Dimension Therapeutics, Inc. (DMTX) was a gene therapy company targeting rare diseases with a focus on liver-directed therapies. Though once promising, the company is no longer operational, rendering its historical financial data and development pipeline irrelevant for current investment considerations. The company's stock is no longer actively traded.
What Is the Investment Thesis for DMTX?
Given that Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and no longer exists as an independent entity, there is no active investment thesis to evaluate. Historical data indicates that the company was focused on developing gene therapies for rare diseases, particularly liver-directed treatments. At the time, potential value drivers included the advancement of their clinical programs, regulatory milestones, and successful commercialization of gene therapies. However, these factors are no longer relevant as the company is defunct. Investors interested in similar therapeutic areas should focus on Ultragenyx (RARE) or other companies actively developing gene therapies.
Based on FMP financials and quantitative analysis
DMTX Key Highlights
- Gross Margin was 100.0% indicating that the cost of goods sold was negligible compared to revenue, though the company's overall profitability was significantly impacted by high research and development expenses.
- Profit Margin was -427.2% reflecting substantial net losses due to the high costs associated with clinical trials and drug development.
- Beta of 4.18 indicating that the stock was highly volatile relative to the market, suggesting higher risk and potential reward (though this is no longer relevant as the company is defunct).
- The company did not pay any dividends, consistent with growth-stage biopharmaceutical companies that typically reinvest earnings into research and development.
- P/E Ratio was -3.04 reflecting the company's negative earnings, a common characteristic of biotech firms investing heavily in R&D before achieving profitability.
Who Are DMTX's Competitors?
DMTX is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical Inc. | $33.88 | +1.23% | $3.34B | — |
| ARIA ARIAD Pharmaceuticals, Inc. | $23.99 | +0.17% | 57 | |
| THPTF Techpoint, Inc. | $19.75 | +0.00% | $363.32M | 50 |
| SAII Software Acquisition Group Inc. II | $8.98 | -5.97% | 44 | |
| ASRPF Asarina Pharma AB (publ) | $2.45 | +0.00% | $41.83M | 43 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DMTX's Key Strengths?
- Proprietary AAV vector technology.
- Focus on liver-directed gene therapy.
- Expertise in rare disease drug development.
What Are DMTX's Weaknesses?
- High R&D costs.
- Regulatory hurdles for gene therapy products.
- Competition from larger pharmaceutical companies.
What Could Drive DMTX Stock Higher?
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing or upcoming catalysts.
What Are the Key Risks for DMTX?
- Negative return on equity (-59.2%) — the business is not currently generating profit on shareholder capital.
- Insider selling — insiders were net sellers of roughly $2.2M recently.
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing or potential risks.
What Are the Growth Opportunities for DMTX?
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
What Opportunities Does DMTX Have?
- Expanding gene therapy applications to new diseases.
- Partnering with larger pharmaceutical companies.
- Securing regulatory approvals for gene therapy products.
What Threats Does DMTX Face?
- Clinical trial failures.
- Adverse events associated with gene therapy.
- Competition from alternative therapies.
What Are DMTX's Competitive Advantages?
- Proprietary AAV vector technology for liver-directed gene therapy.
- Patent protection for gene therapy products and methods.
- Expertise in gene therapy development and manufacturing.
- First-mover advantage in specific rare disease indications.
What Does DMTX Do?
Dimension Therapeutics, Inc., founded with the goal of developing innovative gene therapies, focused on addressing unmet needs in rare genetic diseases. The company's strategy centered around adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to the liver, aiming for long-lasting treatment effects. Dimension Therapeutics pursued programs targeting hemophilia and other inherited metabolic disorders. Their approach involved advanced vector engineering and manufacturing processes to enhance safety and efficacy. Dimension Therapeutics, Inc. was acquired in November 2017 by Ultragenyx Pharmaceutical Inc. After the acquisition, Dimension Therapeutics, Inc. ceased to exist as an independent entity. The company's assets and programs were integrated into Ultragenyx's broader rare disease portfolio. Dimension Therapeutics, Inc. is no longer operational, and its stock is no longer actively traded.
What Products and Services Does DMTX Offer?
- Developed gene therapies for rare diseases.
- Focused on liver-directed gene therapy using AAV vectors.
- Targeted hemophilia and other inherited metabolic disorders.
- Engineered advanced viral vectors for gene delivery.
- Conducted preclinical and clinical trials to evaluate safety and efficacy.
- Sought regulatory approval for their gene therapy products.
- Aimed to provide long-lasting therapeutic effects with single-dose treatments.
How Does DMTX Make Money?
- Focused on research and development of gene therapies.
- Out-licensed or partnered to commercialize therapies.
- Generated revenue through milestone payments and royalties.
- Sought funding through venture capital and public offerings.
What Industry Does DMTX Operate In?
Dimension Therapeutics, Inc. operated within the biopharmaceutical industry, specifically focusing on gene therapy for rare diseases. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying to develop innovative treatments for unmet medical needs. The gene therapy market is projected to experience substantial growth, driven by technological advancements and increasing investment in personalized medicine. Dimension Therapeutics aimed to capitalize on this trend with its liver-directed gene therapy platform before its acquisition.
Who Are DMTX's Key Customers?
- Patients with rare genetic diseases.
- Healthcare providers specializing in genetic disorders.
- Pharmaceutical companies interested in gene therapy collaborations.
- Payers (insurance companies and government healthcare systems).
Net sellingInsider Activity
The most recent 12 insider filings for Dimension Therapeutics, Inc. break down as 11 sales and 1 purchases. On net that is roughly 503K shares disposed (about $2.2M), a signal worth weighing alongside the fundamentals.
DMTX Valuation & Market Position
Relative to its peer group, DMTX's quantitative score of 60/100 is above the peer average of 49/100.
ROE -59%Key Financial Metrics
Return on equity for Dimension Therapeutics, Inc. stands at -59.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.2%, showing how much profit it generates from its asset base. A current ratio of 4.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -32.9%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Dimension Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. DMTX has traded publicly since 2015.
DMTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's pipeline, indicating potential for positive developments ahead.
- Community sentiment has shifted positively as discussions around gene therapy advancements gain traction, highlighting DMTX's innovation.
- Several analysts have noted the promising results from recent clinical trials, which have sparked renewed interest among investors.
- The company's strategic partnerships in the biotech sector are being viewed favorably, enhancing its credibility and potential for growth.
Bear Case
- Concerns over regulatory hurdles for gene therapies have surfaced, creating uncertainty around the approval process for DMTX's products.
- Social sentiment has seen some bearish commentary regarding the company's cash burn rate, raising questions about its financial stability in the near term.
- Recent market volatility in biotech stocks has led to cautious sentiment, with investors wary of potential downturns affecting DMTX.
- Competitors in the gene therapy space are ramping up their efforts, which could overshadow DMTX's advancements and market position.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
DMTX Latest News
No recent news available for DMTX.
DMTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMTX.
Price Targets
Wall Street price target analysis for DMTX.
DMTX MoonshotScore
What does this score mean?
The MoonshotScore rates DMTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Dimension Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Dimension Therapeutics, Inc. do?
Dimension Therapeutics, Inc. was a biopharmaceutical company focused on developing gene therapies for rare genetic diseases, particularly those affecting the liver. Their approach involved using adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to liver cells, aiming for long-term correction of the underlying genetic defects. The company's goal was to create single-dose treatments that could significantly improve the lives of patients with limited or no existing treatment options. However, Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and no longer operates independently.
What do analysts say about DMTX stock?
Given that Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and is no longer a publicly traded entity, there are no current analyst ratings or price targets for DMTX stock. Historical analyst opinions prior to the acquisition may have reflected the potential of the company's gene therapy pipeline and the market opportunity for rare disease treatments. However, these past analyses are no longer relevant for investment decisions, as the company's assets and programs are now part of Ultragenyx's portfolio.
What are the main risks for DMTX?
Since Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. and no longer exists as an independent entity, there are no current risks associated with investing in DMTX. Historically, as a gene therapy company, Dimension Therapeutics faced typical risks associated with the biotechnology industry, including clinical trial failures, regulatory hurdles, competition from other companies developing similar therapies, and the high cost of research and development. However, these risks are no longer applicable to DMTX as a standalone entity.
What are the key factors to evaluate for DMTX?
Dimension Therapeutics, Inc. (DMTX) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does DMTX data refresh on this page?
DMTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DMTX's recent stock price performance?
Dimension Therapeutics, Inc. (DMTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AAV vector technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DMTX overvalued or undervalued right now?
Valuing Dimension Therapeutics, Inc. (DMTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DMTX?
Before investing in Dimension Therapeutics, Inc. (DMTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and no longer exists as an independent entity. All information presented is historical and should not be used for current investment decisions.